AGT and systemic sclerosis: Previous studies indicate that Ang II may be involved in the pathogenesis of SSc [22]–[23], and Ang II blockade has been traditionally used as a vasodilator therapy in renal, pulmonary and cardiac complications in SSc patients [24], [25], [26].